Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

@article{Li2021SubcutaneousEM,
  title={Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors},
  author={Jian Li and Yan-ming Deng and Weijie Zhang and Aiping Zhou and Weijian Guo and Jianwei Yang and Ying Yuan and Liangjun Zhu and Shukui Qin and Silong Xiang and Haolan Lu and John Gong and Ting Xu and David J. Liu and Lin Shen},
  journal={Journal of Hematology \& Oncology},
  year={2021},
  volume={14}
}
Background Monoclonal antibodies targeting programmed death ligand 1 (PD-L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI-H) tumors must be delivered by intravenous infusion. Envafolimab, a humanized single-domain anti-PD-L1 antibody fused to an Fc fragment, represents a potential advance because it can be conveniently administered subcutaneously. Methods This open-label, single-arm, phase 2 study evaluated the efficacy and safety of… 

Figures and Tables from this paper

Envafolimab: First Approval
TLDR
SC envafolimab was recently approved in China for the treatment of adult patients with previously-treated microsatellite instability-high (MSI-H) or deficient MisMatch Repair (dMMR) advanced solid tumours.
Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer
TLDR
How HLA-B evolutionary divergence influences the ICB response in patients with GI cancers is unveiled, supporting its potential utility as a combinatorial biomarker together with TMB for patient stratification in the future.
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
TLDR
A comprehensive overview of the ICI application to treat human tumors alone or in combination with other modalities to support more desired outcomes and lower toxicities in cancer patients is delivered.
Antibodies to watch in 2022.
TLDR
The data show that, with antibodies for COVID-19 excluded, the late-stage commercial clinical pipeline of antibody therapeutics grew by over 30% in the past year, and marketing applications for at least 22 products may occur by the end of 2022.

References

SHOWING 1-10 OF 32 REFERENCES
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
  • D. Le, Tae Won Kim, T. André
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2019
TLDR
Pembrolizumab is effective with a manageable safety profile in patients with MSI-H/dMMR CRC, and the primary end point was objective response rate by RECIST version 1.1 by independent central review.
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
  • A. Marabelle, D. Le, L. Diaz
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2019
TLDR
The study demonstrates the clinical benefit of anti-programmed death-1 therapy with pembrolizumab among patients with previously treated unresectable or metastatic MSI-H/dMMR noncolorectal cancer.
First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors.
TLDR
Subcutaneous envafolimab had a favorable safety and pharmacokinetic profile, with promising preliminary antitumor activity in patients with advanced solid tumors, in a first-in-human, open-label phase I trial.
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
TLDR
JS001 was well tolerated and demonstrated promising anti-tumor activity in UC and RCC as well as in previously underexplored acral and mucosal melanoma subtypes, leading to the initiation of the first prospective anti-PD-1 registration trial in Asia.
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
TLDR
This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab, and high somatic mutation loads were associated with prolonged progression-free survival.
PD-1 blockade in tumors with mismatch repair deficiency.
  • J. Uram, Hao Wang, L. Diaz
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
TLDR
MM status predicts clinical benefit of immune checkpoint blockade with pembrolizumab, and high total somatic mutation loads were associated with PFS.
Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.
TLDR
Clinical application of multiplex sequencing can identify biomarkers of treatment response to contemporary systemic therapies in metastatic esophagogastric cancer and guide strategies to overcome drug resistance, and sheds light on the biological complexity and the dynamic nature of therapeutic resistance.
Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China.
TLDR
KN035 is a novel fusion protein of humanized anti-PD-L1 single domain antibody and human IgG1 Fc fragment formulated for subcutaneous (SC) injection and the escalation phase showed promising results.
...
1
2
3
4
...